INTRODUCTION
G -protein-coupled receptors (Gpcrs) constitute the larGest family of cell surface receptors that respond to a wide range of extracellular stimuli and are involved in virtually all known physiological processes in mammals. 1 Although they respond to diverse agonists, the structural and functional features of these receptors are remarkably conserved. All GPCRs have 7 transmembrane domains and activate a variety of G-protein signaling pathways upon agonist stimulation. 1, 2 There are 4 major Gα protein subfamilies: Gα s , Gα i/o , Gα q , and Gα 12/13 . Gα s stimulates adenylyl cyclase and increases cyclic AMP (cAMP) production, whereas Gα i inhibits cAMP production. Activation of Gα q stimulates phospholipase C β followed by production of diacylglycerol and inositol phosphate, which initiates calcium release from intracellular stores.
Even though GPCRs constitute only a small fraction (15%) of total druggable genes, they account for more than 30% of targets of marketed small-molecule drugs. 3 Due to the enormous historical success of GPCR drug targets, the search for new drugs targeting GPCRs is still the prime focus of many pharmaceutical companies. The completion of the human genome sequence project revealed more than 800 GPCR sequences, of which around 140 GPCRs, excluding olfactory receptors, are still classified as orphan receptors, (i.e., receptors with ligand and physiological functions unknown). 4, 5 Some of these uncharacterized orphan receptors are likely to be novel therapeutic targets of the future. 6, 7 Over the past 2 decades, more than 100 receptors have been deorphanized (i.e., paired with their endogenous ligands). 6, 8 The deorphanization of once-orphaned GPCRs has proven to be fruitful and already unveiled several exciting novel drug targets for treating human diseases, including neurological and neurodegenerative disorders, sleep disorders, inflammation, and rheumatoid arthritis. 6, 7, [9] [10] [11] Human GPR139 (also called hGPCR12, GPRg1, and PGR3) is an orphan receptor that was first described as a receptor homologous to thyrotropin-releasing hormone receptor. 12, 13 GPR139 is extremely well conserved, as the protein sequence of the human receptor is 96% identical to both mouse and rat orthologs. GPR139 shows distant homology to a variety of peptide and chemokine receptors with identities in the range of 20% to 25%. However, it is highly homologous (50% identity) to another orphan receptor, GPR142. 14, 15 The strong homology of GPR139 with GPR142 and weak homology with other GPCRs suggest that GPR139 and GPR142 may form a distinct subbranch of the rhodopsin-type GPCR subfamily. 14 Expression studies in the mouse revealed that GPR139 transcripts were present predominantly in the brain, both in adult and during development. Interestingly, GPR139 showed a much more widespread distribution in the embryonic brain than in the mature central nervous system, indicative of a function for the development of distinct brain areas. 15 In situ hybridization analysis in the brain of adult mice showed high expression levels of GPR139 in the ventrolateral region of the striatum, the median habenular nucleus, and a few other discrete nuclei. 14 Human GPR139 was also found to be expressed at high levels in the caudate, putamen, and medulla and at lower levels in the thalamus. 15 Such strong cross-species consistent expression in the striatum strongly suggests an important role of this receptor in the control of locomotor activity and affective behavior, which are often subject to regulation by the striatum. 14, 15 Understanding of the signaling pathway of a receptor is critical to development of in vitro assays to support drug discovery. 8, 16 The signal transduction pathway of GPR139, however, is still controversial in the literature due to the lack of natural or synthetic ligands. GPR139 was first reported as a Gα q -coupled receptor based on serum response element (SRE) and cAMP response element (CRE) reporter gene transcription assays, 14 but results from a different group using calcium mobilization assays indicated that GPR139 signal was mediated by inhibitory G-proteins. 15 Here we describe detailed characterization of the GPR139 signaling pathway. Overexpression of GPR139 in HEK293F cells increases intracellular cAMP production, indicating GPR139 is a Gα s -coupled receptor. This conclusion was further supported by the identification of a surrogate agonist and several antagonists from the screening of a small-molecule library.
MATERIALS AND METHODS

Materials
Alexa Fluor 594-conjugated mouse anti-hemagglutinin (HA) antibody was from Invitrogen (Carlsbad, CA). Fluoromount-G was from EMS (Hatfield, PA). Rabbit anti-HA antibody was from Zymed Laboratory (South San Francisco, CA). Alpha-Screen cAMP assay kit, OptiPlate-384, and ProxiPlate-384 plates were from PerkinElmer (Boston, MA). Mammalian expression vector of pIRESpuro2 was from BD Biosciences (San Jose, CA). Peptides were from Phoenix Pharmaceuticals (Belmont, CA) or American Peptides Company (Sunnyvale, CA). Neurotransmitter and lipid libraries were from Biomol International (Plymouth Meeting, PA). Unless specified, all cell culture reagents were from Invitrogen, and all other chemicals were from Sigma (St. Louis, MO).
Plasmids, stable cell lines, and cell culture
The genes encoding human GPR139, GPR139A, GPR142, and β 2 adrenergic receptor (β 2 AR) were amplified by PCR from the human cDNA library and cloned into the modified pIRE-Spuro2 vector with an in-frame sequence encoding the HA epitope (YPYDVPDYA) at the N-terminus. The resulting plasmids were used to transfect HEK293F cells or COS-1 cells with Lipofectamine 2000 according to the manufacturer's protocol. Cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM) supplied with 10% fetal bovine serum and penicillin/streptomycin in a 5% CO 2 incubator. Twenty hours after transfection, cells were collected for cAMP measurements as described below (for transient transfection) or selected in DMEM supplemented with various concentrations of puromycin for stable cell lines. GPR139 stable cells were selected with 2.4 µg/mL of puromycin, whereas β 2 AR cells were selected with 0.8 µg/mL of puromycin. Cells stably transfected with empty vector alone were generated by the same procedure and selected with 0.5 µg/mL of puromycin. Clonal GPR139 cells were obtained by limiting dilution from bulk stable HEK293F/ GPR139 cells and screened by receptor expression and response to GPR139 agonist stimulation.
Immunocytochemistry and Western blot
Plasma membrane expression of the receptor was examined by both immunocytochemistry and Western blot analysis. For immunocytochemistry, receptor-expressing cells were seeded onto an 8-chamber slide at a density of a 150,000 cells/well 1 day before the experiment. Cells were washed once with DMEM and then incubated with Alexa Fluor 594-conjugated anti-HA (1:500) in DMEM for 1 h at 37 °C. After washing 3 times with phosphate-buffered saline (PBS), the cells were fixed with 4% paraformaldehyde in PBS at room temperature for 10 min. The slide was sealed with Fluoromount G solution and analyzed by flurorescence microscope. The crude receptor membrane preparations used in Western blots for receptor expression were generated as described previously. 17 Membrane protein concentrations were measured by the Bradford method using bovine serum albumin (BSA) as a standard. A total of 50 µg membrane protein was used for Western blot analysis as described. 18
AlphaScreen cAMP assay
Intracellular cAMP levels were measured by the AlphaScreen cAMP kit according to the manufacturer's protocol. Briefly, cells were grown to 80% confluence and harvested for cAMP measurement. Cells were resuspended in the cAMP stimulation buffer and mixed with anti-cAMP acceptor beads to a concentration of 10 6 cells/mL. Next, 10 µL of cell mixture on a 96-well or 384-well OptiPlate was stimulated with equal volume of various concentrations of compounds as indicated in the figure legend for 30 min at room temperature. Then, 30 µL of detection mix (biotinylated cAMP and streptavidin donor beads were preincubated in the detection buffer for 30 min) was added into each well. For the GPR139 antagonist assay, cells were incubated with antagonist compound diluted at various concentrations for 10 min at room temperature before being stimulated with 10 µM of LP-360924/0.1 µM forskolin solution. The stimulation was stopped by adding 30 µL of detection mix after 20 min of incubation at room temperature. Plates were incubated in the dark overnight before reading with a Fusion or Envision Plate Reader (PerkinElmer), using configurations recommended by the manufacturer. All AlphaScreen signals were converted into cAMP concentrations based on cAMP standard curve and were fit to a sigmoidal dose-response model using the Prism software (GraphPad, San Diego, CA).
High-throughput screening of agonists and antagonists
For agonist screening, HEK293F/GPR139 stable cells were harvested and resuspended in the stimulation buffer as described above. Library compounds in DMSO were first diluted 100fold into stimulation buffer, and then 10 µL of such diluted compound was added into each well of the 384-well OptiPlates (final concentration of compounds was 10 µM in 0.5% DMSO). Cell stimulation was initiated by adding 10 µL of cell/acceptor bead mixture (final concentration = 10,000 cells/well) into the wells containing compound dilutions. Plates were incubated at room temperature for 20 min, and then 30 µL of detection mix was added to each well. After incubating for 15 h at room temperature in the dark, plates were read on a Fusion Plate Reader. All AlphaScreen signals were converted into cAMP concentrations based on cAMP standard curve. Compounds that increased cAMP levels significantly (>15%) in the primary screening were selected and retested at 3 concentrations (1, 3, and 10 µM) against GPR139 and vector control cells. Positive hits that showed more than 2-fold cAMP increase in GPR139 cells at 10 µM concentration, but not in vector cells, were then confirmed in COS-1 or HEK293F cells transiently transfected with GPR139 and further tested by different cAMP assay methods, such as FlashPlate cAMP assay (PerkinElmer) and HitHunter cAMP assay (DiscoveRx, Fremont, CA).
For antagonist screening, clonal stable GPR139-expressing cells (clone #109) were used. First, library compounds in DMSO were diluted 40-fold into cAMP stimulation buffer, and 3 µL of such diluted compounds was dispensed into each well of a 384-well ProxiPlate (final concentration was 10 µM with 0.5% DMSO). Then, 10 µL of HEK293F/GPR139 (#109) cells suspended in stimulation buffer (2 × 10 6 cells/ml) plus anti-cAMP acceptor beads was added into each well. The mixture was incubated for 10 min at room temperature before being stimulated by adding 2 µL of agonist-forskolin solution (75 µM LP-360924 and 0.75 µM forskolin in stimulation buffer). Final concentrations of LP-360924 and forskolin in the assay were 10 and 0.1 µM, respectively. A low concentration of forskolin (0.1 µM final) was included in the assay to increase the screen signal window because the agonist LP-360924 was too weak to generate a robust signal for antagonist screening by itself. Plates were centrifuged briefly and incubated for 20 min at room temperature before 5 µL of detection mix was dispensed into each well. Plates were incubated for 8 to 24 h at room temperature in the dark and read on the Envision Plate Reader. Compounds that showed significant inhibition of LP-360924 activity were picked and confirmed against forskolin-stimulated vector cells at 3 doses (1, 3, and 10 µM). Potential antago nists were further tested against β 2 AR cells stimulated with isoproterenol or vector cells stimulated with forskolin.
RESULTS
Transient transfection of GPR139 in HEK293F cells
One approach widely used in the characterization of orphan GPCR signaling pathway involves analysis of constitutive activity of the receptor, which represents signaling in the absence of an apparent agonist. [19] [20] [21] [22] For orphan receptors with no identified ligand, constitutive activity provides an important lead to receptor signaling pathway. In fact, many GPCRs display measurable constitutive activity, especially in an overexpression system. 21, 23 For Gα s -or Gα i -coupled receptors, constitutive activity leads to change of basal cAMP concentrations. In HEK293F cells transiently transfected with GPR139, strong cell surface receptor expression was detected by immunocytochemistry and Western blot (data not shown), so GPR139 constitutive activity was evaluated following transient transfection using the AlphaSceen cAMP assay, a sensitive cAMP detection method. 24 We first measured the basal cAMP concentrations using a different number of cells. As shown in Figure 1A , basal cAMP levels in GPR139 cells were significantly higher than those in vector cells, even at very low cell density. As a positive control, the β 2 AR, a well-characterized Gα s -coupled receptor, also showed greater increase in cAMP level. The higher basal cAMP level in GPR139-expressing cells suggests that it has a certain level of constitutive activity of Gα s .
Cells expressing constitutively active Gα s -coupled receptors are more sensitive to adenylyl cyclase stimulators, such as forskolin. Thus, forskolin-stimulated cAMP production was measured in transiently transfected GPR139 cells. As shown in Figure 1B , GPR139-expressing cells produced much more cAMP than vector cells upon forskolin stimulation. The entire forskolin dose-response curve was shifted to the left, indicating elevated sensitivity to forskolin in GPR139-expressing cells. Furthermore, dose response of GPR139 cells to isoproterenol (ISO), a β 2 AR agonist, was also shifted to the left (Fig. 1C) . All together, the data indicate that overexpression of GPR139 led to increased basal intracellular cAMP concentration and potentiated the effect of forskolin or isoproterenol in cAMP production, suggesting that GPR139 is a Gα s -coupled receptor with significant constitutive activity.
Stable transfection of GPR139 in HEK293F cells
HEK293F cells stably expressing GPR139 were established and receptor surface expression was examined by immunocytochemistry and Western blot using anti-HA antibodies. GPR139 expression was relatively low in stable cells compared to the transiently transfected cells (data not shown). Nevertheless, basal cAMP levels in GPR139 stable cells were significantly higher than those from control vector cells ( Fig. 2A) . Cells stably expressing β 2 AR showed similar elevation of intracellular cAMP concentration. Interestingly, GPR139 stable cells showed higher basal cAMP concentration than transiently transfected GPR139 cells, even though the receptor expression in stable cells was lower. Consistent with this observation, stable β 2 AR cells also showed higher cAMP level than the transiently transfected cells. In addition, forskolin and isoproterenol-stimulated cAMP productions were measured in these stable cells. The potencies of both forskolin ( Fig. 2B) and isoproterenol (Fig.  2C) were slightly increased, a phenomenon commonly observed in cells overexpressing Gα s -coupled receptors, such as β 2 AR. Thus, the data from both transiently and stably transfected GPR139 cells strongly suggest that the receptor is coupled to Gα s , and activation of GPR139 increases intracellular cAMP production.
Identification of GPR139 agonists
GPR139 was first proposed as a receptor homologous to thyrotropin-releasing hormone receptor, and its ligand was suggested to be a peptide-like molecule. 12 To search for potential GPR139 agonists, we first screened it against our peptide collection, including most of the commercially available peptides from Phoenix Pharmaceuticals and American Peptides using a cAMP assay. However, no agonist activity was identified from the peptide collection. GPR139 was then screened against Biomol neurotransmitter and lipid libraries, but still no specific activity was identified from these libraries.
We then performed high-throughput screening (HTS) of our small-molecule library of approximately 200,000 compounds using the AlphaScreen cAMP assay. A total of 652 compounds from the primary screening showed agonist activity in the activation of GPR139. These compounds were further tested at 3 concentrations (1, 3, and 10 µM) against GPR139 and vector control cells. Compounds that showed more than a 2-fold increase in cAMP level were tested again by other cAMP assay methods. One compound, LP-360924, was identified as a GPR139 agonist (Fig. 3A) . LP-360924 stimulation increased cAMP production by 8-to 10-fold in GPR139 cells but had no effect in vector control cells (Fig. 3B) . Furthermore, the compound did not show any activity in β 2 AR cells at concentrations up to 100 µM (Fig. 3B) , indicating a certain level of specificity of LP-360924 for GPR139. Additional compounds with similar structure in our library were also tested, but all showed weaker activities (data not shown).
The agonist activity of LP-360924 was further tested in COS-1 cells transiently transfected with GPR139. As shown in Figure 4A , LP-360924 stimulated cAMP production only in GPR139-transfected cells, not in vector or β 2 AR-transfected cells. The magnitude of cAMP increase was much smaller in the COS-1 cells than that in HEK293F cells, which may be due to the low level of expression in COS-1 cells based on Western blot analysis (data not shown).
Specificity of LP-360924 was further tested in HEK293F cells transiently transfected with GPR139; GPR139A, an alternative spliced form of GPR139 with a slightly different C-terminal sequence; and GPR142, a GPR139-related receptor with 50% amino acid identity. As expected, LP-360924 stimulated cAMP accumulation in cells expressing either GPR139 or GPR139A (Fig. 4B) , with slightly lower efficacy in GPR139A cells. Surprisingly, LP-360924 was unable to induce any cAMP production in the GPR142 cells, even though the 2 receptors are 50% identical.
We also examined if LP-360924 can uncover other signaling pathways of GPR139 by the fluorescent imaging plate reader (FLIPR) calcium assay. No Ca 2+ mobilization was observed in GPR139 cells after LP-360924 stimulation (data not shown), indicating no Gα q stimulation of GPR139.
Improvement of GPR139 expression
To obtain cells with higher expression of GPR139, we selected clonal cells by limiting dilution from the bulk stable GPR139 cells. More than 160 clones were screened first based on receptor expression by immunocytochemistry using Alexa Fluor 594-conjugated anti-HA antibody and then screened based on the receptor function using cAMP response to LP-360924 stimulation. One cell line (#109) showed the highest receptor expression and the strongest cAMP response to LP-360924 stimulation and was chosen for further study. Based on immunocytochemistry (Fig. 5A, panels A-C) , this clone (panel C) showed much higher receptor expression level than its parent cells (panel B). This conclusion was further supported by the result of Western blot analysis (Fig. 5A, panel D) . GPR139 appeared as 2 major bands with molecular weights around 50 kDa and 58 kDa, which may represent as slightly different posttranslation modification. The expression of both forms of GPR139 was much higher in clone #109 cells than the parent cells. In addition, cells of this clone demonstrated much stronger response to LP-360924 in the functional assay than its parent cells did (Fig. 5B) . Therefore, this clone was selected for antagonist screening of GPR139.
GPR139 antagonists
For antagonist screening, a total of 230,000 compounds were screened at 10 µM in the presence of 10 µM LP-360924 plus forskolin (0.1 µM) using the AlphaScreen cAMP assay. The average Z′ of the entire antagonist screening was 0.6. Compounds that showed 30% to 35% inhibition of LP-360924 activity were retested at 3 concentrations (1, 3, and 10 µM) in parallel against GPR139 (#109) cells stimulated with LP-360924 and vector cells stimulated with 2 µM forskolin. A total of 58 compounds inhibited LP-360924-stimulated cAMP production in GPR139 cells but not vector cells stimulated with forskolin. The most potent antagonists can be classified into 2 groups based on structures. Within each series, a clear, limited structure-activity relationship (SAR) was observed. The first group is the sulfonamide series, represented by LP-471756 ( Fig. 6A) . LP-471756 inhibited specifically LP-360924stimulated cAMP production in GPR139 cells with an IC 50 of approximately 0.64 µM under the assay conditions (Fig.  6B) . The antagonist activity was not observed in forskolinstimulated vector cells or isoproterenol-stimulated β 2 AR cells, even though these cells have similar intracellular cAMP levels (data not shown). The most potent compound from the other group, the triazolopyrimidine series, is LP-114958 ( Fig. 6A) . It also showed GPR139-specific antagonist activity with an IC 50 of 0.67 µM (Fig. 6C) . Again, no antagonist activity was observed in vector and β 2 AR cells.
DISCUSSION
GPR139 is an orphan GPCR predominately expressed in the striatum of the central nervous system, both in human and mouse, and therefore may play an important role in the control of locomotor activity and affective behavior. 14 an orphan receptor, such as GPR139, expression of receptor on the cell surface is the initial step. 8 Human GPR139 was cloned into a modified mammalian expression vector, which provided an N-terminal HA tag to monitor receptor surface expression. In contrast to the published results, 15 GPR139 was expressed efficiently in HEK293F cells by transient transfection. However, the initial effort to generate GPR139 stable cells using 0.5 µg/mL puromycin selection failed with barely detectable receptor expression. After increasing antibiotic selection concentration to 2.4 µg/mL of puromycin, higher expression GPR139 stable cells were obtained. These bulk stable GPR139 cells were used for agonist screening. However, the receptor expression level in the stable cells decreased gradually after a few passages, suggesting its overexpression was detrimental to cell growth. Clonal stable cells of GPR139 (#109) were generated by limiting dilution from bulk stable cells to improve receptor expression level and stability. The clonal stable cells of GPR139 showed much higher and consistent receptor expression and also much stronger response to agonist stimulation. The clonal stable GPR139 cells were successfully used for GPR139 antagonist screening.
The ability to set up screening for compounds targeting an orphan GPCR depends on the identification of receptor signaling pathway. 8 Inconsistent results about the signaling pathway of GPR139 have been reported in the literature. It was first reported to be a Gα q -coupled receptor based on the SRE and CRE reporter gene transcription assay. 14 Interestingly, it was actually observed by Matsuo et al. 14 
that expression of GPR139
increased the CRE-controlled reporter enzyme, even though the authors did not see increased cAMP levels, which could be due to insufficient sensitivity of the cAMP detection assay used. It is not common for purely Gα q -coupled receptors to activate CRE in reporter gene transcription assays. On the other hand, Susens et al. 15 then reported Gα i -coupled activity of GPR139. They observed a reproducible, dose-dependent calcium signal from an acetone extract of brain, which was sensitive to pertussis toxin treatment, indicative of Gα i/o coupling, and to the phospholipase C inhibitor U73122 treatment, indicative of Gα q coupling. Follow-up characterizations showed that GPR139 was predominately coupled to Gα i/o protein. 15 However, the putative brain peptide was never isolated, and therefore no definitive conclusions can be made. Here we described the characterization of the human GPR139 signaling pathway by taking advantage of the receptor constitutive activity. To elucidate the signaling pathway, human GPR139 was overexpressed in HEK293F cells by both transient and stable transfections. Basal levels of cAMP dramatically increased in both transient and stable GPR139 cells when compared to vector control cells. Furthermore, the dose-response curves of forskolin and isoproterenol stimulation in both cells were left-shifted, indicating GPR139 signaling was mediated by Gα s . This conclusion is different from what has been published. The use of different host cells may have caused this. It was reported that the Gα q signal of brain extract on GPR139 was observed only in CHO-K1 cells but not in HEK293 cells, leading to the hypothesis that a cofactor important for GPR139 activation present in CHO-K1 cells is missing in the HEK293 cells. 15 Also, all previously published results were mainly based on reporter gene transcription, which is far downstream of the receptor signaling pathway compared to cAMP production. Therefore, we strongly believe that GPR139 is coupled to Gα s at least in HEK293F cells. It is also possible that GPR139 is a receptor with duality or multiple G-protein coupling, which has been reported for many GPCRs. [25] [26] [27] In contrast to the simple paradigm of 1 receptor/1 class of G-protein, several Gα s -coupled receptors activate dual-signal cascades. For example, β-adrenergic receptor (a classical Gα s -coupled receptor) showed alternative coupling to Gα s and Gα i , a process regulated by PKA, 25 and overexpression of human substance P receptor in CHO cells resulted in direct activation of Gα q , Gα s , and Gα o . 28 Based on the constitutive Gα s -coupling activity of GPR139, an agonist screening campaign was carried out. We identified a compound, designated LP-360924, with GPR139 agonist activity. This compound induced cAMP production in both transient and stable GPR139 cells, confirming that GPR139 is a Gα scoupled receptor. The agonist activity appeared to be specific to GPR139 because the compound showed no activity in vector cells, which express endogenously a large number of Gα s -coupled GPCRs, or in cells overexpressing β 2 AR or GPR142, a receptor showing high sequence homology to GPR139. Nevertheless, broad screening of other GPCRs will still be required to truly define the specificity of this compound.
The availability of an agonist is critical to the understanding of receptor functions in vivo and eventually to the discovery of therapeutic agents. As a starting point, LP-360924 has reasonable in vitro potency and physical properties (e.g., molecular weight = 562.65, logP = 4). Using LP-360924 as an agonist, we were able to identify 2 groups of compounds as antagonists. Again, both compounds showed reasonable potencies. One of them, LP-471756, has several drug-like characteristics 29 -for example, low molecular weight (MW = 329.46), low polar surface area (PSA = 46), and acceptable lipophilicity (logP = 4.9), making this compound an excellent starting point for further drug discovery efforts. The other compound, LP-114958, showed similar potency as LP-471756. This compound exhibits low molecular weight (MW = 390.52) and low polar surface area (PSA = 64) but is extremely lipophilic (logP = 6.5). Such strong hydrophobicity presents challenges to aqueous solubility. However, it would still be considered a reasonable starting point for further optimization.
In summary, we demonstrated that GPR139 activates the Gα s pathway and has constitutive activity, at least when overexpressed in HEK293F cells. We also carried out an HTS campaign based on cAMP increase and identified a series of small-molecule agonists, one of which was characterized in detail. Furthermore, we identified small-molecule antagonists that can block the activity of the agonist compound. These compounds may facilitate the identification of the natural ligand(s) of GPR139 and the understanding of its physiological function in vivo.
